Medhat Ahmed Al-Ghobashy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Medhat Ahmed Al-Ghobashy has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Faten A. Fathalla
National Organization for Research and Control of Biologicals, Egypt
8 shared publicationsMaissa Y. Salem
Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt
8 shared publications- Marianne Nebsen
Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
7 shared publications - Olivia Adly Attallah
Chemistry Department, University of Hartford, West Hartford, CT 06117, USA
5 shared publications Samah S. Abbas
Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Egypt
5 shared publicationsAhmed H. Nadim
Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt
4 shared publications
Latest Publications
- Open Access
- 11 November 2021
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 6 (46) , 31282-31291
Impedimetric Sensors for Cyclocreatine Phosphate Determination in Plasma Based on Electropolymerized Poly(o-phenylenediamine) Molecularly Imprinted Polymers
- 11 November 2021
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 6 (46) , 31282-31291
Open AccessImpedimetric Sensors for Cyclocreatine Phosphate Determination in Plasma Based on Electropolymerized Poly(o-phenylenediamine) Molecularly Imprinted Polymers
- 18 May 2021
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 105 (1) , 249-266
Green and Cost-Effective Extraction Techniques of Quercetin from Mixture of Nutraceuticals with Yield Analysis via Spectrophotometry and High-Performance Liquid Chromatography Methods
Background: Extraction is the leading critical stage in the analysis of nutraceuticals. Ginkgo biloba (GB) has gained interest because of its therapeutic usages. Objectives: The aim was to develop four cost-effective extraction techniques for the extraction of quercetin from GB in a sachet containing a mixture of nutraceuticals. These techniques are solid-phase extraction (SPE), liquid–liquid extraction, inverted dispersive liquid–liquid microextraction, and the QuEChERS (quick, easy, cheap, effective, rugged, and safe) method. Method: Direct spectrophotometry was used to monitor the recovery of the standard quercetin throughout the optimization steps. The HPLC–UV method of analysis was optimized to quantify the yields from the extracts present in the complicated contents of the sachets. The present study was assessed by analytical Eco-Scale assessment (ESA) and the National Environmental Method Index (NEMI) for greenness in comparison with the literature. Results: SPE showed the best cleanup outcomes. ESA and NEMI showed an adequate greenness of the proposed extraction protocol. Conclusions: Quercetin (marker for GB) extraction from market nutraceutical sachets is considered an exemplar for analysis in the QC of nutraceuticals. Regarding the greenness results, the proposed method of extraction is better even with adequate greenness as the extraction was a one-step process, in comparison with multistep processes of previously published protocols. Accordingly, it is recommended for use in routine extraction and analysis of such nutraceuticals. Highlights: Four extraction protocols have been developed. For GB ternary-mixture sachets, proper recovery was obtained using C18 SPE. The assessment of greenness of the proposed protocol guaranteed the superiority of the presented method. Safer sorbents and chemicals are favored for use in routine extraction of nutraceuticals.
- 18 May 2021
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 105 (1) , 249-266
Green and Cost-Effective Extraction Techniques of Quercetin from Mixture of Nutraceuticals with Yield Analysis via Spectrophotometry and High-Performance Liquid Chromatography Methods
Background: Extraction is the leading critical stage in the analysis of nutraceuticals. Ginkgo biloba (GB) has gained interest because of its therapeutic usages. Objectives: The aim was to develop four cost-effective extraction techniques for the extraction of quercetin from GB in a sachet containing a mixture of nutraceuticals. These techniques are solid-phase extraction (SPE), liquid–liquid extraction, inverted dispersive liquid–liquid microextraction, and the QuEChERS (quick, easy, cheap, effective, rugged, and safe) method. Method: Direct spectrophotometry was used to monitor the recovery of the standard quercetin throughout the optimization steps. The HPLC–UV method of analysis was optimized to quantify the yields from the extracts present in the complicated contents of the sachets. The present study was assessed by analytical Eco-Scale assessment (ESA) and the National Environmental Method Index (NEMI) for greenness in comparison with the literature. Results: SPE showed the best cleanup outcomes. ESA and NEMI showed an adequate greenness of the proposed extraction protocol. Conclusions: Quercetin (marker for GB) extraction from market nutraceutical sachets is considered an exemplar for analysis in the QC of nutraceuticals. Regarding the greenness results, the proposed method of extraction is better even with adequate greenness as the extraction was a one-step process, in comparison with multistep processes of previously published protocols. Accordingly, it is recommended for use in routine extraction and analysis of such nutraceuticals. Highlights: Four extraction protocols have been developed. For GB ternary-mixture sachets, proper recovery was obtained using C18 SPE. The assessment of greenness of the proposed protocol guaranteed the superiority of the presented method. Safer sorbents and chemicals are favored for use in routine extraction of nutraceuticals.
- 17 April 2021
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 413 (14) , 3611-3623
Facile imprinted polymer for label-free highly selective potentiometric sensing of proteins: case of recombinant human erythropoietin
In the current study, a molecularly imprinted polymer (MIP)-based potentiometric sensor was fabricated for a label-free determination of recombinant human erythropoietin (rhEPO). The MIP sensor was operated under zero current conditions using tetra-butyl ammonium bromide as a marker ion. A highly ordered rhEPO surface imprinted layer was prepared using 3-aminopropyl triethoxysilane and tetraethoxysilane as a monomer and cross-linker, respectively, under mild reaction conditions. A two-fold increase in the signal output was obtained by polymeric surface minimization (0.5 mm) that allowed more pronounced molecular recognition (imprinting factor = 20.1). The proportion of cross-reactivity was examined using different interfering biomolecules. Results confirmed sensor specificity for both structurally related and unrelated proteins. An ~40% decrease in the response was obtained for rhEPO-β compared to rhEPO-α. The imprinted polymeric surface was evaluated using scanning electron microscopy and Fourier transform infrared spectroscopy. Under the optimal measurement conditions, a linear range of 10.00–1000.00 ng mL−1 (10−10 − 10−8 M) was obtained. The sensor was employed for the determination of rhEPO in different biopharmaceutical formulations. Results were validated against standard immunoassay. Spiked human serum samples were analyzed and the assay was validated. The presence of non-specific proteins did not significantly affect (~8%) the results of our assay. A concentration-dependent linear response was produced in an identical range with detection limit as low as 6.50 ng mL−1 (2.14 × 10−10 M). The facile fabricated MIP sensor offers a cost-effective, portable, and easy to use alternative for biosimilarity assessment and clinical application.
- 17 April 2021
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 413 (14) , 3611-3623
Facile imprinted polymer for label-free highly selective potentiometric sensing of proteins: case of recombinant human erythropoietin
In the current study, a molecularly imprinted polymer (MIP)-based potentiometric sensor was fabricated for a label-free determination of recombinant human erythropoietin (rhEPO). The MIP sensor was operated under zero current conditions using tetra-butyl ammonium bromide as a marker ion. A highly ordered rhEPO surface imprinted layer was prepared using 3-aminopropyl triethoxysilane and tetraethoxysilane as a monomer and cross-linker, respectively, under mild reaction conditions. A two-fold increase in the signal output was obtained by polymeric surface minimization (0.5 mm) that allowed more pronounced molecular recognition (imprinting factor = 20.1). The proportion of cross-reactivity was examined using different interfering biomolecules. Results confirmed sensor specificity for both structurally related and unrelated proteins. An ~40% decrease in the response was obtained for rhEPO-β compared to rhEPO-α. The imprinted polymeric surface was evaluated using scanning electron microscopy and Fourier transform infrared spectroscopy. Under the optimal measurement conditions, a linear range of 10.00–1000.00 ng mL−1 (10−10 − 10−8 M) was obtained. The sensor was employed for the determination of rhEPO in different biopharmaceutical formulations. Results were validated against standard immunoassay. Spiked human serum samples were analyzed and the assay was validated. The presence of non-specific proteins did not significantly affect (~8%) the results of our assay. A concentration-dependent linear response was produced in an identical range with detection limit as low as 6.50 ng mL−1 (2.14 × 10−10 M). The facile fabricated MIP sensor offers a cost-effective, portable, and easy to use alternative for biosimilarity assessment and clinical application.
- 15 October 2019
- Published by Springer Nature in Food Analytical Methods
- Vol. 12 (12) , 2870-2885
Coupling of GC-MS/MS to Principal Component Analysis for Assessment of Matrix Effect: Efficient Determination of Ultra-Low Levels of Pesticide Residues in Some Functional Foods
- 15 October 2019
- Published by Springer Nature in Food Analytical Methods
- Vol. 12 (12) , 2870-2885
Coupling of GC-MS/MS to Principal Component Analysis for Assessment of Matrix Effect: Efficient Determination of Ultra-Low Levels of Pesticide Residues in Some Functional Foods
- 26 September 2019
- Published by The Electrochemical Society in Journal of the Electrochemical Society
- Vol. 166 (14) , B1312-B1320
Nanoparticle-Enhanced Potentiometric Ion-Selective Electrodes for Therapeutic Drug Monitoring of Linezolid
Nosocomial infections caused by multidrug-resistant (MDR) bacteria is treated with Linezolid (LIN) either alone or with other medications such as; Meropenem (MERO) or Theophylline (THEO). LIN has variable pharmacokinetics which makes it an ideal candidate for therapeutic drug monitoring (TDM). Ion selective electrode (ISE) is a promising tool that can be used in hospitals by medical practitioners to adjust the dose of LIN which will eventually improve the therapeutic outcomes. Four potentiometric PVC sensors were fabricated for the determination of LIN in plasma in the presence of co-administered medications (MERO and THEO). Sensor I; cationic exchanger phosphotungstate sensor covering a concentration range of 1.0 × 10−7–1.0 × 10−4 M. while Sensor II; 2–hydroxypropyl-β-cyclodextrin (HP-βCD) sensor covered a concentration range of 1.0 × 10−9–1.0 × 10−3 M. The last two sensors were fabricated using metal nanoparticles (NPs). Sensor III; Copper NP-incorporated HP-βCD sensor was used over a concentration range 1.0 × 10−9–1.0 × 10−3 M, while Sensor IV; Cobalt NP-incorporated HP-βCD sensor attained the highest sensitivity of all the prepared sensors with the quantification range of 1.0 × 10−10–1.0 × 10−4 M. Britton-Robinson buffer at pH 3.5 ± 0.5 was chosen for optimization of experimental conditions of the four sensors. The proposed sensors performance was validated according to IUPAC\FDA guidelines and was applied successfully for the determination of LIN in its pharmaceutical formulation and for TDM in incurred plasma samples. No interference was noted in the presence of (MERO) and (THEO) that are commonly co-administered with LIN as a part of the treatment protocol for healthcare-associated pneumonia (HCAP).
- 26 September 2019
- Published by The Electrochemical Society in Journal of the Electrochemical Society
- Vol. 166 (14) , B1312-B1320
Nanoparticle-Enhanced Potentiometric Ion-Selective Electrodes for Therapeutic Drug Monitoring of Linezolid
Nosocomial infections caused by multidrug-resistant (MDR) bacteria is treated with Linezolid (LIN) either alone or with other medications such as; Meropenem (MERO) or Theophylline (THEO). LIN has variable pharmacokinetics which makes it an ideal candidate for therapeutic drug monitoring (TDM). Ion selective electrode (ISE) is a promising tool that can be used in hospitals by medical practitioners to adjust the dose of LIN which will eventually improve the therapeutic outcomes. Four potentiometric PVC sensors were fabricated for the determination of LIN in plasma in the presence of co-administered medications (MERO and THEO). Sensor I; cationic exchanger phosphotungstate sensor covering a concentration range of 1.0 × 10−7–1.0 × 10−4 M. while Sensor II; 2–hydroxypropyl-β-cyclodextrin (HP-βCD) sensor covered a concentration range of 1.0 × 10−9–1.0 × 10−3 M. The last two sensors were fabricated using metal nanoparticles (NPs). Sensor III; Copper NP-incorporated HP-βCD sensor was used over a concentration range 1.0 × 10−9–1.0 × 10−3 M, while Sensor IV; Cobalt NP-incorporated HP-βCD sensor attained the highest sensitivity of all the prepared sensors with the quantification range of 1.0 × 10−10–1.0 × 10−4 M. Britton-Robinson buffer at pH 3.5 ± 0.5 was chosen for optimization of experimental conditions of the four sensors. The proposed sensors performance was validated according to IUPAC\FDA guidelines and was applied successfully for the determination of LIN in its pharmaceutical formulation and for TDM in incurred plasma samples. No interference was noted in the presence of (MERO) and (THEO) that are commonly co-administered with LIN as a part of the treatment protocol for healthcare-associated pneumonia (HCAP).
- 6 August 2019
- Published by Wiley in Biomedical Chromatography
- Vol. 33 (12) , e4676
Evaluation of the pattern and kinetics of degradation of adalimumab using a stability‐indicating orthogonal testing protocol
Forced degradation studies are crucial for the evaluation of the stability and biosimilarity. Here, adalimumab was subjected to oxidation, pH, temperature, agitation and repeated freeze–thaw in order to generate all possible degradation products. An orthogonal stability‐indicating testing protocol comprising SE‐HPLC, RP‐HPLC, TapeStation gel electrophoresis, dynamic light scattering (DLS), and functional receptor binding assay was developed and validated. The assay protocol was used for the assessment of the pattern and kinetics of aggregation/degradation of adalimumab. SE‐HPLC and DLS were used to show the formation of aggregates/fragments of adalimumab under nondenaturing conditions. TapeStation electrophoresis was performed under denaturing conditions to reveal the nature of aggregates. Results of the receptor binding assay agreed to those of SE‐HPLC and DLS which indicated that it can be used as an activity‐indicating assay for adalimumab. RP‐HPLC demonstrated excellent selectivity for adalimumab in the presence of its oxidized forms. The kinetics of degradation was studied in each case and the results showed that it followed the first‐order reaction kinetics. Correlation between the results supported the quality assessment of the tested product in industrial and clinical settings. This orthogonal protocol is a useful tool in stability assessment of monoclonal antibodies and a key criterion for the biosimilarity assessment.
- 6 August 2019
- Published by Wiley in Biomedical Chromatography
- Vol. 33 (12) , e4676
Evaluation of the pattern and kinetics of degradation of adalimumab using a stability‐indicating orthogonal testing protocol
Forced degradation studies are crucial for the evaluation of the stability and biosimilarity. Here, adalimumab was subjected to oxidation, pH, temperature, agitation and repeated freeze–thaw in order to generate all possible degradation products. An orthogonal stability‐indicating testing protocol comprising SE‐HPLC, RP‐HPLC, TapeStation gel electrophoresis, dynamic light scattering (DLS), and functional receptor binding assay was developed and validated. The assay protocol was used for the assessment of the pattern and kinetics of aggregation/degradation of adalimumab. SE‐HPLC and DLS were used to show the formation of aggregates/fragments of adalimumab under nondenaturing conditions. TapeStation electrophoresis was performed under denaturing conditions to reveal the nature of aggregates. Results of the receptor binding assay agreed to those of SE‐HPLC and DLS which indicated that it can be used as an activity‐indicating assay for adalimumab. RP‐HPLC demonstrated excellent selectivity for adalimumab in the presence of its oxidized forms. The kinetics of degradation was studied in each case and the results showed that it followed the first‐order reaction kinetics. Correlation between the results supported the quality assessment of the tested product in industrial and clinical settings. This orthogonal protocol is a useful tool in stability assessment of monoclonal antibodies and a key criterion for the biosimilarity assessment.
- 23 May 2019
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 11 (25) , 3198-3211
Stability and biosimilarity assessment of infliximab using an orthogonal testing protocol and statistically-guided interpretation of peptide mapping
With the growing number of biosimilars, healthcare providers opt to switch costly originator products with biosimilars. However, extensive data are required to support biosimilarity and interchangeability. In this study, factors affecting physical and chemical stability of infliximab were assessed under various stress conditions to reveal possible degradation products. A set of orthogonal stability- and purity-indicating assays involving size exclusion, reversed phase and ion exchange chromatography in addition to quantitative TapeStation gel electrophoresis, dynamic light scattering, and functional receptor binding assay was developed and used for validation. An objective, statistically-guided interpretation of peptide mapping data using principal component analysis (PM-PCA) was performed to establish a “biosimilarity fingerprint”. SE-HPLC and dynamic light scattering were used to evaluate the formation of aggregates and/or small molecular weight fragments under non-denaturing conditions. Results were correlated with those obtained under denaturing conditions using TapeStation gel electrophoresis. Results indicated that aggregates were formed via non-reducible covalent bonds. RP-HPLC showed no oxidized forms, yet the infliximab biosimilar was relatively more hydrophilic than its innovator counterpart. Ion exchange chromatography revealed slight differences in abundance of the charge variants that were not revealed using other techniques. PM-PCA and receptor binding assay showed differences, yet they were statistically non-significant (P 0.05). Results confirmed similarity in the primary structure, higher order structure and receptor-binding pattern. In-depth investigations of the critical quality attributes of infliximab along with setting up the similarity and range were required. These helped with assessment of the impact of such slight differences on the biosimilarity and interchangeability of the studied product. The developed PM-PCA along with the orthogonal assays helped locate variability that could potentially hinder both biosimilarity and interchangeability of other complex biopharmaceuticals.
- 23 May 2019
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 11 (25) , 3198-3211
Stability and biosimilarity assessment of infliximab using an orthogonal testing protocol and statistically-guided interpretation of peptide mapping
With the growing number of biosimilars, healthcare providers opt to switch costly originator products with biosimilars. However, extensive data are required to support biosimilarity and interchangeability. In this study, factors affecting physical and chemical stability of infliximab were assessed under various stress conditions to reveal possible degradation products. A set of orthogonal stability- and purity-indicating assays involving size exclusion, reversed phase and ion exchange chromatography in addition to quantitative TapeStation gel electrophoresis, dynamic light scattering, and functional receptor binding assay was developed and used for validation. An objective, statistically-guided interpretation of peptide mapping data using principal component analysis (PM-PCA) was performed to establish a “biosimilarity fingerprint”. SE-HPLC and dynamic light scattering were used to evaluate the formation of aggregates and/or small molecular weight fragments under non-denaturing conditions. Results were correlated with those obtained under denaturing conditions using TapeStation gel electrophoresis. Results indicated that aggregates were formed via non-reducible covalent bonds. RP-HPLC showed no oxidized forms, yet the infliximab biosimilar was relatively more hydrophilic than its innovator counterpart. Ion exchange chromatography revealed slight differences in abundance of the charge variants that were not revealed using other techniques. PM-PCA and receptor binding assay showed differences, yet they were statistically non-significant (P 0.05). Results confirmed similarity in the primary structure, higher order structure and receptor-binding pattern. In-depth investigations of the critical quality attributes of infliximab along with setting up the similarity and range were required. These helped with assessment of the impact of such slight differences on the biosimilarity and interchangeability of the studied product. The developed PM-PCA along with the orthogonal assays helped locate variability that could potentially hinder both biosimilarity and interchangeability of other complex biopharmaceuticals.